Last updated: August 18, 2026
CardioGen-82 is a rubidium-82 chloride generator used for positron emission tomography myocardial perfusion imaging. Bracco Diagnostics obtained FDA approval in 2008, but the product’s commercial trajectory was disrupted by a 2011 Class I recall, later supply constraints, and competition from Jubilant DraxImage’s RUBY-FILL generator. Public sources do not disclose CardioGen-82 product revenue, profitability, transaction value, or current U.S. sales. The product’s economic value depends more on installed-site retention, generator reliability, isotope supply, and service infrastructure than on conventional pharmaceutical pricing.
What is CardioGen-82 and how does the product work?
CardioGen-82 is a strontium-82/rubidium-82 generator system. It produces rubidium-82 chloride injection for PET myocardial perfusion imaging in adults with suspected or known coronary artery disease.
Rubidium-82 has a physical half-life of approximately 75 seconds. The short half-life allows imaging without an on-site cyclotron but requires a generator located at the imaging facility. The generator contains strontium-82, which decays to rubidium-82. The system’s commercial utility therefore depends on:
- Generator availability and replacement cycles
- Reliable production of rubidium-82
- Control of strontium-82 and strontium-85 breakthrough
- Dose calibrator and quality-control procedures
- PET scanner access
- Nuclear medicine technologist training
- Regulatory compliance and radioactive-material handling
CardioGen-82 is a combination of a radioactive isotope generator, drug product, delivery system, and service model. Its competitive position cannot be evaluated solely through active-ingredient patent rights.
What is the FDA regulatory status of CardioGen-82?
The FDA approved CardioGen-82 under NDA 022494 in 2008 for PET myocardial perfusion imaging. The approval made it possible for hospitals and imaging centers to conduct rubidium-82 cardiac PET without operating a cyclotron.
CardioGen-82 FDA timeline
| Date |
Event |
Commercial significance |
| 2008 |
FDA approval of CardioGen-82 |
Established Bracco as a commercial supplier of rubidium-82 PET myocardial perfusion technology |
| December 2011 |
FDA Class I recall and market disruption associated with potential strontium breakthrough |
Damaged site confidence and interrupted procedure volumes |
| 2012-2013 |
Corrective actions and return toward commercial availability |
Required renewed hospital validation and regulatory confidence |
| 2016 |
RUBY-FILL received FDA approval |
Introduced a direct U.S. generator competitor |
| 2016 onward |
Public information on CardioGen-82 commercial availability became limited |
Increased uncertainty around market share, supply continuity, and product-level revenue |
The 2011 recall was the central regulatory event in CardioGen-82’s commercial history. The FDA identified a risk that elevated strontium-82 or strontium-85 could be administered to patients if generator performance exceeded acceptable limits. The issue affected confidence in both the product and rubidium-82 PET as an operating model.[1]
What patents protect CardioGen-82?
Publicly available regulatory information does not establish a substantial, currently enforceable Orange Book patent barrier for CardioGen-82. The product’s commercial protection appears to have depended primarily on regulatory approval, generator engineering, manufacturing know-how, isotope supply, quality systems, and customer-service infrastructure.
Are CardioGen-82 patents listed in the Orange Book?
The Orange Book is the relevant FDA database for approved drug products and associated listed patents. Unlike conventional small-molecule drugs, CardioGen-82 is a radioactive generator system with a highly specialized device and manufacturing component. Patent protection may exist outside the Orange Book through:
- Generator architecture
- Strontium-82 production and purification
- Elution and fluid-routing systems
- Radiation shielding
- Breakthrough monitoring
- Dose measurement
- Generator loading and replacement methods
- PET myocardial perfusion imaging protocols
An absence of a material Orange Book patent listing would not eliminate all freedom-to-operate risk. It would, however, reduce the likelihood that a conventional abbreviated new drug application would be blocked by a long-expiring formulation patent.
What is the patent expiration date for CardioGen-82?
No reliable public source establishes a single controlling CardioGen-82 patent expiration date. The product’s original FDA approval did not create a long-term new chemical entity exclusivity period because rubidium-82 is an established radioactive diagnostic agent rather than a newly discovered molecular entity.
Relevant protection is more likely to arise from a portfolio of device, process, and manufacturing patents with different filing dates and expiration dates. Trade secrets and specialized supplier arrangements may remain more important than patent duration.
When does CardioGen-82 lose exclusivity?
CardioGen-82’s principal U.S. exclusivity period was not equivalent to the 12-year biologic exclusivity period or a five-year new chemical entity period.
FDA exclusivity
The likely commercial protection framework was:
- No new chemical entity exclusivity for rubidium-82
- No orphan-drug exclusivity publicly associated with CardioGen-82
- Potential three-year exclusivity only for qualifying new clinical investigations, if granted for a particular supplement
- No known long-duration exclusivity that would prevent competing rubidium-82 products indefinitely
The approval’s practical value came from being an early entrant with an established generator network. That advantage weakened once RUBY-FILL entered the U.S. market.
Patent exclusivity
Patent protection depends on individual generator and manufacturing claims rather than the rubidium-82 molecule. The most durable barriers are likely to be:
- Regulatory validation of isotope purity and breakthrough limits
- Specialized strontium-82 sourcing
- Manufacturing scale and radioactive-material licenses
- Installed-base service contracts
- Hospital protocols and physician familiarity
What patent litigation affects CardioGen-82?
No major publicly established patent litigation campaign involving CardioGen-82 and a generic manufacturer is identified in the principal FDA and public regulatory materials. The main public risk event was regulatory and operational rather than litigation-driven.
The absence of prominent Paragraph IV litigation is commercially significant. It suggests that the principal threat to CardioGen-82 was not a conventional patent challenge against an oral drug. Competition required a separate generator product, FDA approval, isotope supply, and facility implementation.
Which companies are challenging CardioGen-82?
Jubilant DraxImage is the principal publicly identified U.S. competitor through RUBY-FILL, another rubidium-82 generator approved by the FDA in 2016.[2]
| Company |
Product |
Technology |
Competitive position |
| Bracco Diagnostics |
CardioGen-82 |
Rubidium-82 generator |
First major U.S. commercial entrant; later affected by recall and availability concerns |
| Jubilant DraxImage |
RUBY-FILL |
Rubidium-82 generator |
Direct FDA-approved competitor |
| Various PET manufacturers and radiopharmacy suppliers |
N-13 ammonia, F-18 PET agents, emerging cardiac PET agents |
Cyclotron or distributed radiopharmaceutical supply |
Indirect alternatives |
| SPECT manufacturers and radiopharmacy providers |
Technetium-99m and thallium-based imaging |
SPECT myocardial perfusion imaging |
Lower-cost and more widely available substitute in many centers |
RUBY-FILL reduced CardioGen-82’s ability to rely on first-mover status. The two products compete on generator reliability, service responsiveness, isotope logistics, reimbursement economics, scanner utilization, and clinical workflow.
How does CardioGen-82 compare with RUBY-FILL?
CardioGen-82 and RUBY-FILL have broadly similar commercial functions: both provide rubidium-82 for cardiac PET myocardial perfusion imaging.
| Factor |
CardioGen-82 |
RUBY-FILL |
| Sponsor |
Bracco Diagnostics |
Jubilant DraxImage |
| FDA approval |
2008 |
2016 |
| Product type |
Sr-82/Rb-82 generator |
Sr-82/Rb-82 generator |
| Primary use |
PET myocardial perfusion imaging |
PET myocardial perfusion imaging |
| Key commercial strength |
Early installed base and clinical familiarity |
Newer competitive platform and alternative supply option |
| Main risk |
Recall history and supply continuity concerns |
Limited market size and dependence on cardiac PET adoption |
| Core barrier |
Generator manufacturing and isotope logistics |
Same |
| Substitution risk |
SPECT, N-13 ammonia, other PET agents |
Same |
Neither generator has the same volume potential as a mass-market chronic medicine. Cardiac PET remains a facility-intensive service. The addressable market is constrained by PET scanner availability, reimbursement, referral patterns, and radiopharmaceutical operations.
What is the market size and competitive landscape for rubidium-82 cardiac PET?
The rubidium-82 market is a specialized diagnostic market rather than a broad pharmaceutical category. Demand is driven by cardiac PET adoption, not by the total population with coronary artery disease.
Market drivers
CardioGen-82 and RUBY-FILL benefit from:
- Higher diagnostic performance of PET myocardial perfusion imaging in appropriate patients
- Growth in cardiology imaging centers with PET capability
- Increased use of quantitative myocardial blood-flow assessment
- Demand for alternatives to technetium-based SPECT
- Short procedure times and the absence of an on-site cyclotron
Market constraints
The market is constrained by:
- High PET scanner capital costs
- Need for nuclear medicine infrastructure
- Generator handling and radioactive-material licensing
- Limited isotope supply
- Generator replacement and maintenance requirements
- Reimbursement variability
- Competition from SPECT
- Limited number of high-volume cardiac PET centers
The short rubidium-82 half-life is operationally attractive but creates a strict dependence on generator uptime. A manufacturing interruption can quickly reduce or eliminate a site’s ability to perform rubidium-82 PET procedures.
What drove the CardioGen-82 financial trajectory?
Public filings do not provide audited CardioGen-82 revenue, gross margin, operating profit, or cumulative sales. Bracco is privately held, and product-level financial reporting is limited. Any precise revenue estimate would therefore be speculative.
The financial trajectory can be divided into four phases.
1. Launch and category creation
The 2008 approval gave Bracco an early position in a developing cardiac PET market. Revenue was generated through generator placements, radiopharmaceutical supply, service agreements, and repeat generator replacement.
The product’s economic model likely had recurring characteristics. A generator installation can create continuing revenue from replacement units, service, quality control, and consumables. That structure is more valuable than a single-dose product model when sites maintain high procedure volumes.
2. Recall-driven contraction
The 2011 recall created direct financial pressure through:
- Lost or deferred procedure volume
- Product returns and replacement costs
- Customer remediation
- Regulatory and quality-system expenditures
- Lost confidence among hospital purchasers
- Delayed expansion of cardiac PET programs
The recall also imposed an opportunity cost. Hospitals considering new cardiac PET programs could defer investment or select alternative imaging modalities.
3. Recovery and competitive pressure
After corrective actions, CardioGen-82 could compete on clinical familiarity and installed infrastructure. The recovery was limited by the need to rebuild customer confidence and by the emergence of a second FDA-approved generator.
RUBY-FILL changed the procurement dynamic. Hospitals gained a second supplier, which weakened single-source pricing power and reduced the strategic value of CardioGen-82’s first-mover position.
4. Mature or declining commercial visibility
Public reporting provides limited evidence of current CardioGen-82 sales. The product’s reduced visibility may reflect constrained supply, a smaller active installed base, commercial discontinuation, or migration by sites to RUBY-FILL and other imaging options. The available public record does not support a precise conclusion about the product’s current revenue level.
How strong is the CardioGen-82 patent estate?
CardioGen-82 has a moderate technology-based protection profile but a weak conventional pharmaceutical exclusivity profile.
Stronger protection areas
- Specialized generator engineering
- Radiation-safety and breakthrough-control systems
- Strontium-82 procurement
- Radioactive-material manufacturing licenses
- Quality-control validation
- Customer installation and service capability
- Hospital workflow integration
Weaker protection areas
- No apparent durable molecule-level exclusivity
- No clear long-term FDA exclusivity barrier
- Availability of a competing FDA-approved rubidium-82 generator
- Substitution by SPECT and other PET agents
- Limited evidence of active Orange Book patent enforcement
The strongest barrier is execution. A competitor needs more than an equivalent chemical composition. It needs validated radioactive manufacturing, reliable isotope supply, regulatory approval, and a service organization capable of supporting imaging centers.
What generic entry risks exist for CardioGen-82?
Traditional generic entry risk is limited because CardioGen-82 is not a conventional tablet or injectable drug supplied from a standard pharmaceutical plant.
The principal entry scenarios are:
- A competing rubidium-82 generator with FDA approval
- A device or combination-product challenge based on equivalent generator performance
- Substitution by another cardiac PET radiopharmaceutical
- Conversion of imaging sites to SPECT
- Loss of supply reliability that forces customers to change platforms
A Paragraph IV challenge could theoretically target listed patents, but the commercial relevance would depend on whether CardioGen-82 had active Orange Book-listed claims at the time of filing. The public record does not identify a major Paragraph IV case that materially shaped the product’s market.
What manufacturing and intellectual-property barriers protect CardioGen-82?
Manufacturing barriers are more important than composition-of-matter patents.
Isotope supply
Strontium-82 is produced through specialized accelerator and target-processing operations. Supply is concentrated and sensitive to reactor, cyclotron, target, purification, and transport constraints. Any interruption can affect multiple generator suppliers.
Radioactive manufacturing
The sponsor must maintain:
- Radioactive-material licenses
- Validated production facilities
- Shielded manufacturing and shipping systems
- Radiochemical purity testing
- Strontium breakthrough testing
- Dose calibration procedures
- Batch release controls
- Distribution systems compatible with short-lived rubidium-82
Service infrastructure
A generator product requires field service, replacement scheduling, site qualification, and technical support. These capabilities create switching costs even when the underlying isotope is not proprietary.
What licensing deals affect CardioGen-82?
No major publicly disclosed licensing or acquisition transaction has been identified as the primary driver of CardioGen-82’s market position. Bracco Diagnostics commercialized the product under its own corporate platform.
Because Bracco is privately held, detailed licensing economics, royalty rates, manufacturing-transfer agreements, and site-level commercial contracts are not generally available through public-company filings.
What is the likely generic launch scenario?
A conventional generic launch is unlikely to be the principal disruption mechanism. The more realistic scenario is platform substitution.
Base-case scenario
CardioGen-82 retains value at sites with established workflows, physician familiarity, and compatible service support. Growth remains limited by the size of the cardiac PET market and competing generator availability.
Downside scenario
Supply interruptions, generator retirement, or service degradation accelerate migration to RUBY-FILL, SPECT, or other PET agents. Revenue falls faster than procedure demand because customers may change platforms rather than wait for supply normalization.
Upside scenario
Cardiac PET reimbursement improves, more cardiology centers install PET scanners, and the sponsor restores dependable generator supply. The product benefits from recurring site demand, although market expansion remains infrastructure-dependent.
What is the revenue exposure for Bracco?
CardioGen-82 revenue exposure cannot be quantified from public disclosures. Bracco does not publish a detailed product-level income statement for the product.
The revenue model likely includes:
- Generator sales or placements
- Replacement generators
- Radiopharmaceutical charges
- Service contracts
- Technical support
- Site qualification and maintenance
Revenue quality depends on active generator sites and average monthly procedures per site. A small number of high-volume centers could represent a large share of total product demand, creating concentration risk. Conversely, broad placement across hospitals can stabilize demand but raises service and logistics costs.
Geographic coverage and international market potential
The United States is the most important identifiable market because CardioGen-82 and RUBY-FILL have FDA regulatory histories and U.S. cardiac PET adoption has supported generator-based imaging.
International growth faces separate constraints:
- Country-specific radiopharmaceutical approvals
- Nuclear-material licensing
- Local isotope supply
- PET scanner penetration
- Reimbursement rules
- Transport limits for radioactive materials
- Local manufacturing or distribution requirements
The same short half-life that makes rubidium-82 useful also increases dependence on local generator deployment. This favors markets with concentrated, high-volume cardiac imaging centers rather than fragmented outpatient networks.
Key Takeaways
- CardioGen-82 is a rubidium-82 generator for PET myocardial perfusion imaging, not a conventional small-molecule drug.
- Bracco received FDA approval in 2008 under NDA 022494.
- The 2011 Class I recall was the product’s most important regulatory and commercial disruption.
- RUBY-FILL, approved in 2016 and marketed by Jubilant DraxImage, is the principal direct U.S. competitor.
- Public sources do not disclose CardioGen-82 product revenue or profitability.
- No durable molecule-level exclusivity is apparent for rubidium-82.
- Patent value is concentrated in generator design, manufacturing, quality systems, and related know-how.
- Traditional Paragraph IV and generic-tablet risks are limited.
- The main commercial risks are supply reliability, isotope availability, service continuity, reimbursement, and competition from SPECT and other PET agents.
- The product’s financial trajectory depends on cardiac PET adoption and active installed sites rather than broad prescription volume.
FAQs
Is CardioGen-82 still commercially available?
Public information does not establish a reliable current commercial-availability position. Its market history includes a major recall, later supply disruptions, and competition from RUBY-FILL.
Is CardioGen-82 a biologic drug?
No. CardioGen-82 is a radioactive drug-device generator system that produces rubidium-82 chloride for PET imaging.
Can a generic manufacturer copy CardioGen-82?
A conventional generic manufacturer would face substantial regulatory, radioactive-material, manufacturing, and isotope-supply requirements. The realistic competitor is another FDA-approved generator platform.
Does CardioGen-82 have a five-year new chemical entity exclusivity period?
No publicly established five-year new chemical entity exclusivity period applies to CardioGen-82. Rubidium-82 is an established diagnostic radionuclide.
Which product competes most directly with CardioGen-82?
RUBY-FILL from Jubilant DraxImage is the clearest direct U.S. competitor because it is also an FDA-approved rubidium-82 generator for cardiac PET myocardial perfusion imaging.
References
-
U.S. Food and Drug Administration. (2011). CardioGen-82 strontium breakthrough recall and safety communications. FDA.
-
U.S. Food and Drug Administration. (2016). RUBY-FILL, NDA 208881: Approval letter and prescribing information. FDA.
-
U.S. Food and Drug Administration. (2008). CardioGen-82, NDA 022494: Approval letter and prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
American Society of Nuclear Cardiology. (2018). Position statements and practice guidance for myocardial perfusion PET. Journal of Nuclear Cardiology.
